Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants

Documenti analoghi

• Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males
  di: Heejae Won, et al.
  Pubblicazione: (2024)
• Clinical characteristics and risk factors for escalation to anaphylaxis from non‐severe drug hypersensitivity reaction
  di: Hyo‐In Rhyou, et al.
  Pubblicazione: (2025)
• Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20
  di: Ryan P. Nolan, et al.
  Pubblicazione: (2024)
• Efficacy and safety of CT‐P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16‐week follow‐up study
  di: Clive Grattan, et al.
  Pubblicazione: (2025)
• No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
  di: Wonsuk Shin, et al.
  Pubblicazione: (2024)